多囊性肾病市场－全球产业规模、份额、趋势、机会和预测，按类型、按治疗类型、按最终用户、按地区和竞争进行细分，2020 年至 2030 年

2024 年全球多囊性肾病变 (PKD) 市值为 5.0239 亿美元，预计到 2030 年将达到 7.5869 亿美元，预测期内复合年增长率为 7.11%。 PKD 是一种遗传性疾病，其特征是肾臟中长出充满液体的囊肿，导致肾臟逐渐肿大并最终导致肾衰竭。全球范围内常染色体显性和隐性 PKD 盛行率的上升、诊断能力的提高以及研究投入的增加推动了市场扩张。精准医疗的进步使得基于个别基因图谱的更有针对性的治疗方法成为可能。患者数量的不断增长，加上医疗保健专业人员意识的提高以及早期检测的基因筛检的结合，刺激了对有效治疗方案的需求。製药公司和研究机构越来越注重开发创新干预措施，以延缓疾病进展并改善患者预后，从而推动市场成长。

关键市场驱动因素

多囊性肾病变（PKD）盛行率不断上升

主要市场挑战

治疗费用高昂

主要市场趋势

遗传学研究的进展

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：全球多囊性肾病变市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依类型（常染色体显性多囊性肾病变 (ADPKD)、常染色体隐性多囊性肾病变 (ARPKD)、其他）
  • 依治疗类型（诊断、药物/疗法）
  • 按最终使用者（医院和诊所、门诊护理中心、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 按类型
  • 按治疗类型
  • 按最终用户
  • 按地区

第五章：亚太多囊肾市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按类型
  • 按治疗类型
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第六章：欧洲多囊性肾病市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第七章：北美多囊性肾病变市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第八章：南美多囊性肾病变市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第九章：中东和非洲多囊性肾病市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：市场动态

• 驱动程式
• 挑战

第 11 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 12 章：全球缺铁性贫血：SWOT 分析

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Otsuka Pharmaceuticals
• Camber Pharmaceuticals
• Apotex Corp
• Ascend Laboratories
• Par Pharmaceuticals
• Teva Pharmaceutical Industries
• Merck KGA
• Accord Healthcare
• Pfizer Inc.
• PD-Rx Pharmaceuticals, Inc

第 15 章：策略建议

第16章调查会社について・免责事项

The Global Polycystic Kidney Disease (PKD) Market was valued at USD 502.39 million in 2024 and is projected to reach USD 758.69 million by 2030, growing at a CAGR of 7.11% during the forecast period. PKD is a genetic condition characterized by the growth of fluid-filled cysts in the kidneys, leading to progressive kidney enlargement and eventual renal failure. Market expansion is being propelled by a rising global prevalence of both autosomal dominant and recessive forms of PKD, improved diagnostic capabilities, and increased research investment. Advancements in precision medicine are enabling more targeted therapeutic approaches based on individual genetic profiles. The growing patient population, combined with heightened awareness among healthcare professionals and the integration of genetic screening for early detection, has stimulated demand for effective treatment options. Pharmaceutical companies and research institutions are increasingly focused on developing innovative interventions to delay disease progression and enhance patient outcomes, thereby fueling market growth.

Key Market Drivers

Increasing Prevalence of Polycystic Kidney Disease (PKD)

The rising incidence of PKD worldwide is a major growth catalyst for the market. As a hereditary condition, PKD has seen growing diagnosis rates due to enhanced screening and genetic testing. Autosomal dominant PKD (ADPKD) affects approximately 1 in every 400 to 1,000 people, while autosomal recessive PKD (ARPKD) occurs in 1 in 20,000 to 40,000 individuals. With healthcare systems adopting more robust diagnostic practices, particularly among individuals with a family history of the disease, the patient pool is expanding. Increased awareness among clinicians and the general public has led to earlier detection and intervention, promoting demand for both supportive and disease-modifying therapies. As the affected population grows, pharmaceutical investment in PKD-focused research and treatment innovation is also accelerating.

Key Market Challenges

High Treatment Costs

The high cost associated with PKD treatment continues to hinder broader access and adoption of advanced therapies. Management of PKD often requires lifelong monitoring, imaging, nephrology consultations, and eventually renal replacement therapies such as dialysis or kidney transplantation in advanced cases. Limited availability of approved and cost-effective medications further compounds the financial burden on patients. Targeted drugs that are in clinical development or recently approved tend to be expensive, making them inaccessible to many, particularly in low-resource settings. Additionally, the long-term costs of managing disease progression and complications place pressure on both patients and healthcare systems, posing a substantial challenge to the market's growth and equitable treatment access.

Key Market Trends

Advancements in Genetic Research

Ongoing progress in genetic research is significantly influencing the PKD treatment landscape. Identification of mutations in genes such as PKD1 and PKD2 has facilitated the development of personalized treatment strategies and innovative therapies targeting the molecular mechanisms driving cyst formation. Gene-editing technologies and pharmacogenomics are enabling the design of more effective and potentially curative interventions. Furthermore, the discovery of reliable biomarkers is supporting early diagnosis, disease monitoring, and patient stratification for clinical trials. These advancements are streamlining drug development and paving the way for precision medicine in PKD care. Collaborations among geneticists, pharmaceutical companies, and advocacy groups are accelerating these efforts, increasing the pace at which research translates into clinical practice and market offerings.

Key Market Players

• Otsuka Pharmaceuticals
• Camber Pharmaceuticals
• Apotex Corp
• Ascend Laboratories
• Par Pharmaceuticals
• Teva Pharmaceutical Industries
• Merck KGA
• Accord Healthcare
• Pfizer Inc.
• PD-Rx Pharmaceuticals, Inc

Report Scope:

In this report, the Global Polycystic Kidney Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Polycystic Kidney Disease Market, By Type:

• Autosomal dominant polycystic kidney disease (ADPKD)
• Autosomal recessive polycystic kidney disease (ARPKD)
• Others

Global Polycystic Kidney Disease Market, By Treatment Type:

• Diagnosis
• Drug/Therapy

Global Polycystic Kidney Disease Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Global Polycystic Kidney Disease Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Polycystic Kidney Disease Market.

Available Customizations:

Global Polycystic Kidney Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Polycystic Kidney Disease Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Autosomal dominant polycystic kidney disease (ADPKD), Autosomal recessive polycystic kidney disease (ARPKD), Others)
  • 4.2.2. By Treatment Type (Diagnosis, Drug/Therapy)
  • 4.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Treatment Type
  • 4.3.3. By End User
  • 4.3.4. By Region

5. Asia Pacific Polycystic Kidney Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Treatment Type
  • 5.2.3. By End User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Polycystic Kidney Disease Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Treatment Type
      • 5.3.1.2.3. By End User
  • 5.3.2. India Polycystic Kidney Disease Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Treatment Type
      • 5.3.2.2.3. By End User
  • 5.3.3. Australia Polycystic Kidney Disease Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Treatment Type
      • 5.3.3.2.3. By End User
  • 5.3.4. Japan Polycystic Kidney Disease Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Treatment Type
      • 5.3.4.2.3. By End User
  • 5.3.5. South Korea Polycystic Kidney Disease Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Treatment Type
      • 5.3.5.2.3. By End User

6. Europe Polycystic Kidney Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Polycystic Kidney Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Germany Polycystic Kidney Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Spain Polycystic Kidney Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By End User
  • 6.3.4. Italy Polycystic Kidney Disease Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Treatment Type
      • 6.3.4.2.3. By End User
  • 6.3.5. United Kingdom Polycystic Kidney Disease Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Treatment Type
      • 6.3.5.2.3. By End User

7. North America Polycystic Kidney Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Polycystic Kidney Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Mexico Polycystic Kidney Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By End User
  • 7.3.3. Canada Polycystic Kidney Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By End User

8. South America Polycystic Kidney Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Polycystic Kidney Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By End User
  • 8.3.2. Argentina Polycystic Kidney Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Colombia Polycystic Kidney Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By End User

9. Middle East and Africa Polycystic Kidney Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Polycystic Kidney Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Saudi Arabia Polycystic Kidney Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By End User
  • 9.3.3. UAE Polycystic Kidney Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Iron Deficiency Anemia: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Otsuka Pharmaceuticals
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Camber Pharmaceuticals
• 14.3. Apotex Corp
• 14.4. Ascend Laboratories
• 14.5. Par Pharmaceuticals
• 14.6. Teva Pharmaceutical Industries
• 14.7. Merck KGA
• 14.8. Accord Healthcare
• 14.9. Pfizer Inc.
• 14.10. PD-Rx Pharmaceuticals, Inc

15. Strategic Recommendations

16. About Us & Disclaimer